Day: November 25, 2020

AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020.Conference Presentation DetailsConference: Evercore ISI 3rd Annual HealthCONxFormat: Fireside chat with Umer RaffatPresenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, Shattuck’s Vice President of Finance and Corporate StrategyDate: December 2, 2020Time: 1:00 p.m. ESTWebcast Link: Available HereThe live webcast of the fireside chat will be available on the Events &...

New York, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) — Mallard Acquisition Corp. (NASDAQ: MACUU) (the “Company”) announced that, commencing November 27, 2020, holders of the units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s common stock and warrants included in the units. Common stock and warrants that are separated will trade on the Nasdaq Capital Market under the symbols “MACU” and “MACUW,” respectively. Those units not separated will continue to trade on the Nasdaq Capital Market under the symbol “MACUU.”This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration...

TORONTO, Nov. 25, 2020 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE: CLS)(TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced it will hold an analyst and investor meeting on December 2 at 4:00pm ET. During the meeting, Celestica’s management will provide an overview of Celestica’s Joint Design and Manufacturing business, and will reaffirm Q4 2020 guidance and outline near-term expectations.To participate in the conference call in listen-only mode, please dial (647) 788-4919 or 1 (877) 291-4570. To ensure your participation, please call in approximately ten minutes prior to the scheduled start of the call. Analysts will have the opportunity for a Q&A with speakers following the formal remarks.A webcast is also available at:https://onlinexperiences.com/Launch/QReg/ShowUUID=D17311B8-8E5F-460E-A143-D9B5E264D255 A...

NASHVILLE, Tenn., Nov. 25, 2020 (GLOBE NEWSWIRE) — Healthcare Realty Trust Incorporated (NYSE:HR) today announced the release of its second annual Corporate Responsibility Report covering Environmental, Social, and Governance (ESG) initiatives and accomplishments. The report includes the Company’s initial Key Performance Indicator (KPI) targets that are aligned with the U.N. Sustainable Development Goals.The Company also announced that it has expanded Carla Baca’s responsibilities to include leading the Company’s Corporate Responsibility initiatives. Ms. Baca joined the Company in 2011 and currently oversees investor relations. Healthcare Realty’s sustainability reports, principles and policies are available on the Company’s website: https://www.healthcarerealty.com/sustainability/Healthcare Realty Trust is a real estate investment...

MONTRÉAL, Nov. 25, 2020 (GLOBE NEWSWIRE) — Nemaska ​​Lithium Inc. (“Nemaska Lithium” or the “Corporation”) announces today that it has completed the previously announced exchange of its common shares, on a one-for-one basis, for common shares of NMX Residual Liabilities Inc. (“Residual Nemaska Lithium”), resulting in Residual Nemaska Lithium having become a successor reporting issuer under applicable Canadian securities laws (the “Exchange”). All issued and outstanding options, warrants and other securities of the Corporation (including securities convertible, exchangeable or exercisable for shares of the Corporation) have also been cancelled for no consideration. The Exchange was effected and completed in accordance with and pursuant to the approval and vesting order of the Superior Court of Québec (Commercial Division) issued...

MONTRÉAL, 25 nov. 2020 (GLOBE NEWSWIRE) — Nemaska Lithium Inc. (« Nemaska Lithium » ou la « Société ») annonce aujourd’hui qu’elle a réalisé l’échange annoncé précédemment de ses actions ordinaires, au pair, contre des actions ordinaires d’Obligations résiduelles NMX Inc. (l’« entité restante de Nemaska Lithium »), aux termes duquel l’entité restante de Nemaska Lithium est devenue un émetteur assujetti remplaçant en vertu des lois sur les valeurs mobilières canadiennes applicables (l’ « échange »). Tous les bons de souscription, options et autres titres de la Société émis et en circulation (y compris les titres permettant d’obtenir des actions de la Société par conversion, échange ou exercice) ont également été annulés sans contrepartie. L’échange a été effectué et réalisé conformément à l’ordonnance d’approbation et de dévolution...

CB2 receives majority shareholder approval for all 3 resolutions proposed.CB2 will release Q3 2020 financial results and MD&A after market close on Monday November 30th, 2020 and subsequently host its earnings call on Tuesday December 1, 2020 at 9 am EDT.CB2 will begin trading under its new name, Skylight Health Group Inc., and new ticker symbol “SHG” on the Canadian Securities Exchange on Monday November 30, 2020.TORONTO, Nov. 25, 2020 (GLOBE NEWSWIRE) — CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), one of the largest multi-specialty healthcare systems in the United States, is pleased to announce that it has received majority vote for all 3 resolutions proposed in its special meeting of the shareholders held November 23, 2020. The table below shows the percentage in favor for each of the 3 resolutions.The...

HOUSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) — Crown Castle International Corp. (NYSE: CCI) (“Crown Castle”) announced today that Dan Schlanger, Crown Castle’s Executive Vice President and Chief Financial Officer is scheduled to present on Wednesday, December 9, 2020 at 1:30 p.m. Eastern Time at the Barclays Global TMT Conference. The presentation will be broadcast live over the Internet and is expected to last approximately 25 minutes. The live webcast link and presentation for the conference will be available on Crown Castle’s website at www.crowncastle.com, where it will also be archived for replay.ABOUT CROWN CASTLECrown Castle owns, operates and leases more than 40,000 cell towers and approximately 80,000 route miles of fiber supporting small cells and fiber solutions across every major U.S. market. This nationwide portfolio...

HOUSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) — Crown Castle International Corp. (NYSE: CCI) (“Crown Castle”) announced today that Dan Schlanger, Crown Castle’s Executive Vice President and Chief Financial Officer is scheduled to present on Tuesday, December 8, 2020 at 11:10 a.m. Eastern Time at the UBS Global TMT Virtual Conference. The presentation will be broadcast live over the Internet and is expected to last approximately 40 minutes. The live webcast link and presentation for the conference will be available on Crown Castle’s website at www.crowncastle.com, where it will also be archived for replay.ABOUT CROWN CASTLECrown Castle owns, operates and leases more than 40,000 cell towers and approximately 80,000 route miles of fiber supporting small cells and fiber solutions across every major U.S. market. This nationwide...

GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) — Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference.About NVX-CoV2373NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen...